Clinical trial · Observational
Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM
Comparison of Clinical Efficacy of Liver Resection, Radiofrequency Ablation, Transarterial Chemoembolization, and Drug Therapy in Patients with Liver Metastasis of Gastrointestinal Stromal Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to evaluate the overall survival benefits of local treatment combined with imatinib(IM) and IM alone in patients suffering from GIST liver metastases. The main question it aims to answer is: • Whether IM combined with hepatic resection (HR) or other local treatments such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) has better long-term survival benefits compared to IM monotherapy. Patients are divided into different treatment groups: * IM group * IM combined with HR group * IM combined with RFA or TACE group Researchers will compare the IM + HR group and IM + RFA/TACE group with the IM group to see if it has a better Overall survival (OS).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| GIST, Malignant | Malignant Gastrointestinal Stromal Tumor | ALIAS | 0.90 |
| Liver Metastases | Gastrointestinal Stromal Tumor | PROBABILISTIC | 0.70 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| hepatic resection (HR) | Procedure | — | UNRESOLVED |
| imatinib (IM) | Drug | Imatinib | ALIAS |
| radiofrequency ablation (RFA) | Procedure | — | UNRESOLVED |
| transarterial chemoembolization (TACE) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- IM group
- description
- Imatinib(IM)
- interventionNames
- Drug: imatinib (IM)
- label
- IM combined with HR group
- description
- Imatinib(IM) combined with hepatic resection(HR)
- interventionNames
- Drug: imatinib (IM)
- Procedure: hepatic resection (HR)
- label
- IM combined with RFA or TACE group
- description
- Imatinib(IM) combined with radiofrequency ablation (RFA) or transarterial chemoembolization (TACE)
- interventionNames
- Drug: imatinib (IM)
- Procedure: radiofrequency ablation (RFA)
- Procedure: transarterial chemoembolization (TACE)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Pathological evidence of GIST of primary tumors * Liver metastases evidenced by biopsy or radiological findings * Sufficient liver, hematologic, and renal function, coupled with an Eastern Cooperative Oncology Group performance status score ranging from 0 to 1 Exclusion Criteria: * IM was not used during treatment * Liver metastases appeared on second-line or later subsequent lines of TKI * Combined with other malignant tumors * Failure to follow up
References
Publications (0)
Data not yet available